StrategyIntermediate7 min read

Vertical Market Strategy

Vertical market strategy means deliberately serving one industry deeply (life sciences, restaurants, dental practices, construction) rather than building a general tool any industry can use. Vertical players win on workflow fit: the product encodes the regulatory, operational, and terminology specifics of one industry — software you couldn't use in any other vertical without massive rebuilds. This trades market size for win rate. A horizontal CRM addresses every business; a dental-practice CRM addresses 200,000 US clinics. But the vertical version closes 50%+ of qualified deals because it understands HIPAA, dental coding, and front-desk workflows out of the box.

Also known asVertical SaaSIndustry-Specific StrategyVertical FocusVertical Specialization

Challenge a friend Browse library

The Trap

The trap is calling yourself 'vertical' when you're really just 'horizontal with a marketing skin.' True vertical strategy means engineering for industry-specific workflows: HL7 integrations for healthcare, FDA 21 CFR Part 11 compliance for pharma, restaurant POS-to-kitchen-printer protocols for restaurants. If you could rip out the industry references from your product and resell to another industry, you're horizontal. Buyers see through skin-deep verticalization quickly. The other trap: TAM compression. Choose a vertical too small (e.g., independent jewelers — 28K US locations) and you'll hit a ceiling at $50M ARR.

What to Do

Pick a vertical with: (1) at least 50,000 addressable buyers, (2) acute pain that is industry-specific (regulatory, workflow, integrations), (3) limited tech sophistication of incumbents (legacy software written in the 90s is gold), (4) willingness to pay (regulated industries usually pay more). Build the product to serve the vertical's NON-product needs too: industry-specific onboarding content, vertical events presence, integrations with vertical-specific systems. Hire from the industry — your CRO and CSM should have walked the buyer's halls. KnowMBA's view: vertical-vs-horizontal is rarely a binary. Most successful 'vertical' players (Veeva, Toast) ARE horizontal in tech foundation but vertical in workflow, sales, integrations, and brand. Plan to be vertical first, then optionally expand into adjacent verticals once you dominate one.

Formula

Vertical TAM = (# addressable companies) × (avg ACV) × (estimated penetration ceiling, typically 40-60%)

In Practice

Veeva Systems built its $30B+ market cap by serving life sciences exclusively. It started as Salesforce's life-sciences CRM (built on Salesforce platform) but deeply specialized: integrations with FDA submission systems, sample management workflows for pharma reps, validated environments for clinical trials, GxP compliance baked in. By 2020, Veeva had ~80% market share among the top 20 pharma companies. A horizontal CRM with 'pharma features' could never replicate this — Veeva's product reflects 15+ years of life-sciences-specific engineering.

Pro Tips

01
Vertical SaaS typically achieves 2-3x higher retention than horizontal SaaS in the same segment because the product is deeply embedded in industry workflows. Veeva has 95%+ gross retention; Salesforce has 88-92%.
02
Vertical players typically command 30-50% pricing premiums over horizontal alternatives because the buyer trusts industry-specific solutions to handle compliance/regulatory edge cases.
03
The best vertical strategies expand into adjacent verticals only after dominating the first. ServiceTitan started in HVAC, expanded to plumbing (similar buyer), electrical, then pest control. Each expansion was 1-2 verticals at a time, not a horizontal pivot.

Myth vs Reality

Myth

“Vertical SaaS has too small a TAM to build a billion-dollar company”

Reality

Veeva ($30B), Toast ($15B), Procore ($8B), ServiceTitan ($9.5B last private valuation) — all vertical. The math works: 100K buyers × $30K avg ACV × 40% penetration = $1.2B ARR potential per vertical.

Myth

“You should add features for adjacent verticals to grow”

Reality

Premature horizontal expansion is the #1 killer of vertical SaaS. Spreading product roadmap across 3 verticals before dominating 1 means you do all 3 mediocrely. Win one vertical first.

Try it

Run the numbers.

Pressure-test the concept against your own knowledge — answer the challenge or try the live scenario.

🧪

Knowledge Check

You sell project management software to general contractors. Win rate is 35%. Sales cycles are 90 days. A growth investor suggests pivoting to 'all professional services' (lawyers, consultants, accountants) to expand TAM 5x. What is the right diagnostic question?

Industry benchmarks

Is your number good?

Calibrate against real-world tiers. Use these ranges as targets — not absolutes.

Vertical SaaS Win Rate vs Horizontal Alternative

Win rate of vertical-specialized SaaS in their target industry vs horizontal competitors

Dominant Vertical Position

> 50%

Strong Vertical

30-50%

Modest Edge

15-30%

No Real Vertical Advantage

< 15%

Source: OpenView Partners Vertical SaaS Benchmark Report

Real-world cases

Companies that lived this.

Verified narratives with the numbers that prove (or break) the concept.

💊

Veeva Systems

2007-2024

success

Veeva built its CRM exclusively for life sciences (pharma, biotech, medical devices) on the Salesforce platform. By specializing deeply — sample management, FDA submission integrations, validated GxP environments, life-sciences-specific data model — Veeva captured ~80% of the top 20 pharma companies as customers. Today Veeva is a $30B+ market cap company with 95%+ gross retention. A horizontal CRM could not have built equivalent depth without abandoning its other 50 industries.

Market Cap (2024)

$30B+

Top-20 Pharma Penetration

~80%

Gross Revenue Retention

~95%

Years to $1B ARR

~12 years

A 'platform' alone doesn't beat verticalization. Veeva built ON Salesforce but won AGAINST Salesforce in life sciences because vertical depth — workflow, integrations, regulatory — beats horizontal generality at the buyer's desk.

Source ↗

🍞

Toast

2011-2024

success

Toast built a restaurant-only POS and operating system. By focusing exclusively on restaurants, they engineered for industry-specific needs: kitchen printer protocols, tip pooling, table-management workflows, delivery integrations (DoorDash, UberEats), inventory tied to menu items, payroll for tipped employees. By 2024, Toast served 100,000+ restaurant locations and had crossed $4B in revenue. Square (horizontal POS) tried to compete with restaurant features but consistently lost head-to-head deals because Toast's purpose-built workflows save 5-10 hours per week per restaurant.

Restaurant Locations Served

100,000+

Revenue (2024)

$4B+

Market Cap

$15B+

Win Rate vs Square in Restaurants

60%+

Workflow specificity is the moat. Toast's product reflects 100s of restaurant-specific decisions; horizontal POS players can't copy them all without abandoning their non-restaurant verticals.

Source ↗

Decision scenario

Vertical Focus vs Horizontal Expansion

You run a $30M ARR SaaS for dental practices (8,000 customers, $30K ACV avg). Growth is 50% YoY. Your board wants you to expand into veterinary clinics (similar workflow profile, 28,000 US clinics) to '2x your TAM.'

ARR

$30M

Customers (Dental)

8,000

Win Rate (Dental)

55%

Gross Retention

94%

Untapped Dental TAM

192,000 clinics × ~80% still

Decision 1

Your current dental product captures only 4% of US dental clinics. Win rate is 55% in dental. You haven't even hit Crossing the Chasm in your core market. Veterinary requires a different sales motion (clinic chain consolidators vs solo dentists), different integrations (vet-specific PIMS), and different terminology.

Expand into veterinary now — TAM is the constraint on valuation multiplesReveal

You hire a vet sales team and split engineering 60/40 dental/vet. After 18 months, vet ARR is $3M (40 customers, 25% win rate, slow ramp). Dental ARR growth slows from 50% YoY to 30% because product velocity halved. Combined ARR at month 24: $48M. Had you stayed focused, dental alone would have hit $67M (50% × 50% compound). Multiple compression: investors now see two underperforming product lines instead of one dominating one.

ARR (24 mo): $30M → $48M (vs $67M if focused)Win Rate (Dental): 55% → 48% (less product investment)

Stay focused on dental — there's $5B+ in untapped dental ARR to capture before adjacent verticals make senseReveal

You double down: deeper integrations with dental imaging, insurance billing, patient communication. Dental ARR compounds 60% YoY for 3 more years. By year 4, you're at $120M ARR with 65% gross margin and 130% NRR. NOW you expand into veterinary — funded by dental, hiring a vet GM with industry experience, with 2x the engineering velocity. Vet hits $20M ARR within 18 months because you have war chest and credibility.

ARR (Year 4): $30M → $120M (focused)Gross Margin: Improved to 65%

Related concepts